21.09.2017 • News

Envigo Appoints Chief Commercial Officer and President of EMEA Operations

Envigo has made two new appointments to its Executive Committee. The appointments of Craig Boyd as Chief Commercial Officer (CCO) and Lizanne Muller as President of EMEA Operations have been made at a time of growth for Envigo during which the organization has been focused on improving the quality of the customer experience for its global customer base across the pharmaceutical, chemicals, and crop protection industries. Both of the positions report directly into CEO Dr. Adrian Hardy.

Craig Boyd, who has joined Envigo in the position of CCO, has more than 20 years’ experience in various global pharmaceutical markets and has worked extensively in the US, Asia, Europe and Australia. Boyd was the Executive Vice President of Mayne Pharma’s US specialty brands division before joining Envigo. Prior to this, Boyd led the global commercial sales functions at Hospira and Mylan, and spent 10 years as a senior commercial sales and marketing executive at Novartis. In his new role, Boyd is responsible for Envigo’s global commercial organization, including, sales, marketing, pricing and customer service activities.

Lizanne Muller, who has joined Envigo as President EMEA Operations, has 18 years’ experience working within a multinational pharmaceutical manufacturing company, and brings with her extensive commercial experience, specializing in operational finance, continuous improvements, regulatory compliance and change management. Prior to joining Envigo, Muller spent 16 years at the Dishman Group serving in a variety of roles of increasing responsibility including Vice President of Compliance and Governance. Muller is accountable for Envigo’s Contract Research Services and Research Services Models operations across Europe and Asia.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read